Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.76 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.76 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373247 | 0.90 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12373263 | 0.89 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11PIK3CG | |
| SCHEMBL12373264 | 0.89 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11PIK3CG | |
| SCHEMBL12373259 | 0.87 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11PIK3CG | |
| SCHEMBL12373280 | 0.86 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12373257 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11PIK3CG | |
| SCHEMBL2273194 | 0.83 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12373228 | 0.83 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11PIK3CG | |
| SCHEMBL2276476 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12373273 | 0.81 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| EP-2266981-B1 | Benzothiazole compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-7994337-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994337-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2266981-A2 | Benzothiazole compounds useful as kinase inhibitors | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090118272-A1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090118272-A1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-7473784-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473784-B2 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070185175-A1 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185175-A1 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| WO-2007016392-A2 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118272-A1 | BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | GRK2, MAPK9, MAPK1 | MAPK14 59/4885MAPK13 47/4885MAPK12 54/4885 |
| US-20070185175-A1 | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | GRK2, MAPK1, GRK4 | MAPK14 63/4885MAPK13 53/4885MAPK12 58/4885 |
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK13 685/4885MAPK12 538/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | MAPK14 523/4885MAPK13 685/4885MAPK12 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.